Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings

[1] Hoffmann CJ(2009)Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa Clin Infect Dis 49 1928-1935

[2] Charalambous S(2017)Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring Lancet Infect Dis. 17 e26-e29

[3] Sim J(2018)HIV viral load point-of-care testing: the what, the whys and the wherefores Sex Transm Infect. 94 394-395

[4] Ledwaba J(2011)Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil Rev Inst Med Trop Sao Paulo 53 301-307

[5] Schwikkard G(2004)The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment Int J STD AIDS 15 538-542

[6] Chaisson RE(2016)CD38 as surrogate marker for HIV infection in antiretroviral naive and antiretroviral experienced patients in Kenya Adv Mol Diag. 1 107-51

[7] Peter T(2010)Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths Scand J Immunol 71 45-370

[8] Ellenberger D(2014)Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection Mediat Inflamm 2014 198413-70

[9] Kim AA(2016)Human Galectin-9 is a potent mediator of HIV transcription and reactivation PLoS Pathog 12 e1005677-2092

[10] Boeras D(2009)Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with < 50copies/ml HIV-1 RNA J Clin Virol 46 367-681

[1] Hoffmann CJ(2009)Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa Clin Infect Dis 49 1928-1935

[2] Charalambous S(2017)Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring Lancet Infect Dis. 17 e26-e29

[3] Sim J(2018)HIV viral load point-of-care testing: the what, the whys and the wherefores Sex Transm Infect. 94 394-395

[4] Ledwaba J(2011)Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil Rev Inst Med Trop Sao Paulo 53 301-307

[5] Schwikkard G(2004)The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment Int J STD AIDS 15 538-542

[6] Chaisson RE(2016)CD38 as surrogate marker for HIV infection in antiretroviral naive and antiretroviral experienced patients in Kenya Adv Mol Diag. 1 107-51

[7] Peter T(2010)Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths Scand J Immunol 71 45-370

[8] Ellenberger D(2014)Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection Mediat Inflamm 2014 198413-70

[9] Kim AA(2016)Human Galectin-9 is a potent mediator of HIV transcription and reactivation PLoS Pathog 12 e1005677-2092

[10] Boeras D(2009)Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with < 50copies/ml HIV-1 RNA J Clin Virol 46 367-681